RT Journal Article
SR Electronic
T1 Risk factors, early presentations, and clinical markers of Parkinson’s disease in Primary Care in a diverse UK population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.30.21264336
DO 10.1101/2021.09.30.21264336
A1 Simonet, Cristina
A1 Bestwick, Jonathan
A1 Jitlal, Mark
A1 Ben-Joseph, Aaron
A1 Marshall, Charles R.
A1 Dobson, Ruth
A1 Marrium, Soha
A1 Robson, John
A1 Lees, Andrew J.
A1 Giovannoni, Gavin
A1 Cuzick, Jack
A1 Schrag, Anette
A1 Noyce, Alastair J.
YR 2021
UL http://medrxiv.org/content/early/2021/10/02/2021.09.30.21264336.abstract
AB Importance Predictors of future Parkinson’s disease (PD) have been suggested through population-based studies, but these studies over-represent white, affluent groups and may not be generalisable.Objective To investigate the association between risk factors and pre-diagnostic presentations of PD in a uniquely diverse UK population, with universal access to health care.Design, Setting, and Participants A case-control study was conducted in East London, using primary care health records.Main outcomes and Measures Logistic regression was used to determine associations between risk factors and pre-diagnostic presentations of PD with final diagnosis. Three periods (recorded <2 years, 2-5 years, and 5-10 years prior to diagnosis) were analysed.Results Primary care records were available for 1,055 patients with PD and 1,009,523 controls. The strongest associations were found for tremor (OR, 181.69; 95% CI, 151.91-217.31) and ‘memory complaints’ (OR, 9.84; 95% CI, 7.39-13.11), <2 years before PD diagnosis. However, associations for both complaints persisted up to 10 years prior to PD diagnosis. Shoulder pain was more common in those who developed PD, emerging 5 to 10 years prior to diagnosis (OR, 2.54; 95% CI, 1.77-3.65), and may be a surrogate marker for rigidity. Epilepsy showed a strongest association with subsequent PD (OR, 5.14; 95% CI, 1.26-21.0), and associations were also found for hypertension (OR, 1.71; 95% CI, 1.34-2.17) and type 2 diabetes (OR, 1.57; 95% CI, 1.31-1.87) 5 to 10 years before diagnosis. We replicated several known associations with early non motor features including hypotension, constipation, and depression. A weak but novel association was observed with prodromal hearing loss and subsequent PD, which appeared up to 10 years prior to diagnosis. No associations with future PD diagnosis were found for ethnicity or deprivation index.Conclusions and relevance This study provides further evidence that a range of comorbidities and pre-diagnostic presentations are encountered in primary care prior to PD diagnosis, but for the first time in such a diverse and deprived population. Convincing temporal associations were observed for epilepsy and hearing loss with subsequent PD. The predominance of ‘memory symptoms’ hints at an excess of cognitive dysfunction in early PD in this population or difficulty in correctly ascertaining symptoms in traditionally under-represented groups.Question What are the pre-diagnostic manifestations of Parkinson’s disease (PD) that present to primary care in a diverse and deprived population with universal access?Findings Tremor and ‘memory symptoms’ were reported up to 10 years before diagnosis and were most strongly associated with PD. Several recognised pre-diagnostic features were replicated, but novel temporal associations between epilepsy and hearing loss with subsequent PD were observed.Meaning The range of symptoms that cause people to present to primary care, up to a decade before PD diagnosis, are broad. The strength of association, relative importance and interpretation of prodromal features may vary according to the population studied.Competing Interest StatementThe authors have declared no competing interest.Funding Statementhe Preventive Neurology Unit is funded by the Barts Charity. JR was funded by Barts Charity and by Health Data Research UK, an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. AS was supported by the NIHR UCLH Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The general practitioners as data controllers approved the research uses of this data. The data used was based on routinely collected data in general practitioner electronic health records which is deidentified and published using aggregate counts and did not require ethics committee approval. The Clinical Effectiveness Group is the data processor, and the General Practices in the four CCGs are the data controllers. CEG has the written consent of all practices in the study area to use pseudonymised patient data for audit and research for patient benefit. The researchers adhere to the data protection principles of the Data Protection Act 2018, and all data was managed according to UK NHS information governance requirements. All outputs were in the form of aggregate patient data. The NHS Health Research Authority toolkit (http://www.hra-decisiontools.org.uk/ethics/) identified that Research Ethics Approval was not required for this project as all data is pseudonymised and presented in aggregate form. This was confirmed by the Chair of the North East London Strategic Information Governance Network. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.